IceCure Medical Advances FDA Review
Werte in diesem Artikel
IceCure Medical(NASDAQ:ICCM) reported second-quarter 2025 results on Aug. 13, 2025, with revenue declining year-over-year to $1.25 million from $1.75 million for the six months ended June 30, 2025. The company highlighted regulatory progress for its ProSense system in breast cancer, a $10 million rights offering to strengthen liquidity, and expanding clinical validation in international markets. Key strategic updates center on the U.S. Food and Drug Administration (FDA) review, financial runway, and global adoption momentum.The de novo marketing authorization request for ProSense is under active review by the FDA, with a comprehensive post-market study protocol submitted as requested. The FDA's requirements include a 400-patient, 30-site post-market commitment, which is shaping operational planning for the company.Successful FDA approval would represent a major inflection point for IceCure Medical, potentially accelerating U.S. commercial adoption and long-term revenue growth.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Ausgewählte Hebelprodukte auf Icecure Medical
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Icecure Medical
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: MotleyFool
Nachrichten zu Icecure Medical Ltd.
Analysen zu Icecure Medical Ltd.
Keine Analysen gefunden.